Gossamer Bio, Inc., a San Diego, CA-based new biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products to address high unmet needs of targeted patient populations, raised $100m in Series A funding.
The round was co-led by Arch Venture Partners and Omega Funds. In conjunction with the funding, Richard Lim and Otello Stampacchia of Omega Funds, Kristina Burow and Robert Nelsen of ARCH Venture Partners, and Tom Daniel, former Chairman and President of Celgene Global Research and Early Development, joined Gossamer Bio’s Board of Directors.
The company intends to use the funds to advance its pipeline of clinical and pre-clinical stage programs.
Co-founded by Faheem Hasnain and Sheila Gujrathi, M.D., former executive leadership of Receptos, Inc., Gossamer Bio focuses on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. The company will leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Gossamer Bio will initiate development of its lead program, a Ph2b/3 oral, once daily therapy targeting specific patients across different indications with the potential for a pipeline within a product.
The company’s pipeline includes other clinical and preclinical stage assets in multiple disease areas.